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Editors: Anton N. Sidawy and Bruce A. PerlerThe effect of warfarin therapy on endoleak development after
endovascular aneurysm repair (EVAR) of the abdominal aorta
Joseph L. Bobadilla, John R. Hoch, Glen E. Leverson, Girma Tefera
Objectives: The presence of an endoleak after endovascular abdominal
aortic aneurysm (AAA) repair (EVAR) may predispose to sac expansion and
potential sac rupture. The incidence of endoleak after AAA repair can be
as high as 20% to 30%. We investigated whether warfarin anticoagulation
was an independent risk factor for endoleak after EVAR for AAA.
Methods: All AAA patients who underwent elective EVAR were prospectively
followed-up. Data for demographics, clinical comorbidities, outcomes, EVAR
devices, and anticoagulation methods were recorded. All patients under-
went routine follow-up at 1, 6, and 12 months and annually thereafter.
Computed tomography angiography (CTA) with 3-dimensional (3D) volu-
metric analysis was also completed.
Results: During a 7-year period, 127 consecutive patients with infrarenal
AAAs who underwent EVAR were monitored for a mean of 2.14 years. The
average age at the time of EVAR was 73.8 years. Warfarin therapy alone
was administered to 24 patients, and anticoagulation with antiplatelet
therapy alone was administered to 103. During the study period, 38 (29.9%)
endoleaks were documented. The overall endoleak rate was 13 of 24 in the
warfarin group and 25 of 103 in the antiplatelet group (P = .004). CTA 3D volu-
metric aneurysm sac analysis showed an increase of 16.09% in the warfarin
study group and a reduction of 9.71% in the antiplatelet group (P = .04).
Conclusions: Anticoagulation with warfarin appears to be linked to an
increased risk for the development of endoleak after EVAR, specifically type
II. Volumetric analysis showed warfarin therapy also contributed to persis-
tent aneurysm sac expansion. These data suggest that patients who require
warfarin anticoagulation for other indications should be advised that they
might be at an increased risk for the development of endoleaks, subsequent
secondary interventions, persistent sac expansion, and possible delayed sac
rupture.The impact of radiation dose exposure during endovascular aneurysm
repair on patient safety
Claire Jones, Stephen A. Badger, Christopher S. Boyd, Chee V. Soong
Objective: Endovascular aneurysm repair (EVAR) exposes patients to radia-
tion during the procedure and in subsequent follow-up. The study goal was
to calculate the radiation dose in our unit and compare it against other pub-
lished data and national guidelines.
Methods: All EVAR procedures were identified from a prospectively main-
tained database. Radiation dose, screening time, and volume of intravenous
contrast during the procedure were reviewed. Radiation exposure from
subsequent computed tomography (CT) imaging was included in the overall
exposure. Results are expressed as mean  standard deviation.* Full articles available online at www.jvascsurg.org
1078e5884/$36.00
doi:10.1016/S1078-5884(10)00419-3Results: From October 1998 to October 2008, 320 elective patients under-
went EVAR. Mean screening time was 29.4  23.3 minutes, and the radiation
dose was 11.7  7.1 mSv. The EVAR was an emergency in 64 patients. The
mean screening time was 22.9  18.2 minutes, and the radiation dose was
13.4  8.6 mSv. During the first postoperative year, follow-up CT scans
exposed the patients to 24.0 mSv, with 8.0 mSv in subsequent years. Abdom-
inal radiographs added an additional 1.8 mSv each year.
Conclusion: EVAR and the follow-up investigations involve substantial
amounts of radiation, with well-recognized carcinogenic risks. Because
patient safety is paramount, radiation exposure should be minimized. This
may be possible by standardizing radiation exposure throughout the United
Kingdom by implementing national guidelines and considering other imaging
modalities for follow-up.Long-term follow-up of neck expansion after endovascular aortic
aneurysm repair
Thomas S. Monahan, Timothy A.M. Chuter, Linda M. Reilly, Joseph H. Rapp,
Jade S. Hiramoto
Objective: This study determined the rate, extent, and clinical significance
of neck dilatation after endovascular aneurysm repair (EVAR).
Methods: The study included 46 patients who underwent elective EVAR
using bifurcated Zenith stent grafts (Cook, Bloomington, Ind) and had at
least 48 months of clinical and radiographic follow-up. Computed tomog-
raphy images were analyzed on a 3-dimensional workstation (TeraRecon,
San Mateo, Calif). Neck diameter was measured 10 mm below the most
inferior renal artery in planes orthogonal to the aorta. Nominal stent graft
diameter was obtained from implantation records.
Results: Median follow-up was 59 months (range, 48-120 months). Neck
dilation occurred in all 46 patients. The rate of neck dilation was greatest
at early follow-up intervals. At 48 months, median neck dilation was 5.3
mm (range, 2.3-9.8 mm). The extent of neck dilation at 48 months
correlated with percentage of stent graft oversizing (Spearman r = 0.61,
P < .001). No type I endoleak or migration >5 mm occurred.
Conclusions: After EVAR with the Zenith stent graft, the neck dilates until
its diameter approximates the diameter of the stent graft. Neck dilation
was not associated with type I endoleak or migration of the stent graft.Catheter-based neurosalvage for acute embolic complication during
carotid intervention
Mao-Shin Lin, Ying-Hsien Chen, Chi-Chao Chao, Cheng-Hsin Lin, Hung-Yuan
Li, Chia-Lun Chao, Ming-Fong Chen, Hsien-Li Kao
Objectives: Iatrogenic emboli may be released during carotid intervention,
causing permanent neurologic complications and catastrophic outcomes.
This article reports the procedural details and clinical results of our series
Abstracts 285of neurosalvage techniques to manage thromboembolic events during
carotid procedures.
Methods: Between March 2003 and December 2007, 342 patients (283 men,
72.1  8.9 years old, 121 symptomatic) underwent percutaneous stent
deployment in 407 cervical internal carotid arteries in our institution. Visible
distal embolization with flow occlusion caused neurologic complications in
10 patients (2.5%), and a structured and stepwise neurosalvage approach
was attempted.
Results: Guidewire fragmentation and microcatheter injection of heparin
and nitroglycerin were performed in all 10 patients as step 1. Intra-arterial
thrombolysis was given in four patients and balloon angioplasty in five, as
step 2. Intracranial stenting was done in one patient as the last step.
Successful angiographic recanalization (Thrombolysis in Myocardial Infarc-
tion [TIMI] grade 2-3) occurred in 9 of 10 (90%). Residual neurologic sequel
was observed in five, including three patients with hemorrhage complica-
tions (1 received emergent craniotomy). There was no neurologic mortality
in this series.
Conclusions: Acute embolic complication during carotid artery stenting can
be managed by catheter-based neurosalvage with effective angiographic
recanalization and marginal clinical success.Below knee bare nitinol stent placement in high-risk patients with critical
limb ischemia is still durable after 24 months of follow-up
Konstantinos P. Donas, Giovanni Torsello, Arne Schwindt, Eva Scho¨nefeld,
Olga Boldt, Georgios A. Pitoulias
Background: This study evaluated the durability of nitinol stent placement
in high-risk patients with chronic critical limb ischemia (CLI) and infrapopli-
teal lesions after suboptimal balloon angioplasty.
Methods: Between January 2006 and January 2009, 53 high-risk patients (24
women; mean age, 71.8  5.1 years) with CLI underwent infragenicular stent
placement with a 4F sheath-compatible self-expanding nitinol stent. Patients
had three or more serious cardiopulmonary comorbidities, including chronic
obstructive pulmonary disease, congestive heart failure, coronary artery
occlusive disease, American Society of Anesthesiologists score 3, previous
myocardial infarction, coronary stent or bypass, or infection after peripheral
revascularization. Endovascular therapy was performed in 30 stenoses and 23
occlusions in 53 patients. The mean stenosis length was 5.5  1.9 cm. The
mean occlusion length was 6.5  2.9 cm. The mean follow-up was 24.1  7.3
months and consisted of clinical examination, ankle-brachial index (ABI)
measurements, and duplex ultrasound imaging. Digital subtraction angiog-
raphy was performed if restenosis or reocclusion was suspected.
Results: The technical success rate was 98.1%. The 24-month cumulative
primary patency rate was 75.5%. During the follow-up, two patients under-
went successful repeat angioplasty, and four patients required crural
bypass. The 24-month secondary patency and freedom from amputation
rates were 88.7% and 88.7%, respectively. The mean ABI increased signifi-
cantly at 12 and 24 months (P < .001). Risk stratification to detect predictors
that influenced the patency rate showed that proximal lesions had signifi-
cant better patency than distal crural lesions (83.3% vs 65.2%, P = .04).
The morphology of the lesions (stenoses vs occlusions, P = .88) did not seem
to influence primary patency. Four patients died from nonprocedure-related
causes during the follow-up, including lung cancer, myocardial infarction,
and glioblastoma multiforme. No procedure-related deaths were recorded.
Conclusions: The 2-year outcome of our series underscores the value of
infrapopliteal nitinol stent placement as a durable bailout treatment option
in high-risk CLI patients with suboptimal angioplasty.
From the Midwestern Vascular Surgical Society
A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin
(Angiomax), in patients undergoing lower extremity bypass
Vikram S. Kashyap, Paul D. Bishop, James F. Bena, Karen Rosa, Timur P.
Sarac, Kenneth Ouriel
Objective: Replacing heparin with bivalirudin has been beneficial in
patients undergoing coronary intervention and coronary artery bypass. The
use of this alternative anticoagulant during peripheral bypass operations
has not been studied. Concerns over distal thrombosis using this direct
thrombin inhibitor (DTI) prompted a single-arm, open-label, pilotprospective trial of bivalirudin in patients undergoing lower extremity
bypass to assess perioperative safety and efficacy.
Methods: Between 2006 and 2007, 18 patients met criteria for enrollment
and underwent primary lower extremity bypass using bivalirudin. All
patients had severe symptomatic atherosclerotic disease requiring lower
extremity bypass. Bivalirudin at a bolus dose of 0.75 mg/kg and continuous
infusion of 1.75 mg/kg/hr was used as the sole anticoagulant.
Results: Patients (mean age, 67 years) underwent femoral-popliteal (n = 14)
or femoral-tibial (n = 4) bypass preferentially using saphenous vein (83%).
Mean operative time was 261 minutes, with bivalirudin infusion time of 95
 26 minutes (mean  standard deviation). Reliable anticoagulation was
achieved with weight-based dosing with activated clotting time values at
baseline (systemic) of 131  92 seconds, during infusion (systemic) of 347
 36 seconds, and from the distal vasculature (limb) of 345  66 seconds.
Distal limb bivalirudin levels were stable at 9755  3860 ng/mL during clamp
occlusion. Mean estimated blood loss was 332  191 mL with four patients
(22%) requiring blood products. One patient required revision of the prox-
imal anastomosis during the initial hospitalization. At 30 days, all bypass
operations were patent with improvement of mean ankle-brachial index
from 0.57 to 0.81. There were no deaths, myocardial infarctions, or ampu-
tations in the 30-day postoperative period. Based on the Thrombolysis in
Myocardial Infarction classification for bleeding, one patient had major
bleeding (>2 units of packed red blood cells), and three patients had minor
bleeding within the first 30 days.
Conclusions: Bivalirudin is a safe and effective anticoagulant for lower
extremity bypass operations. Thrombosis beyond the distal clamp was not
seen. A comparative trial to standard anticoagulation is warranted.
From the Western Vascular Society
Classification of proximal endovenous closure levels and treatment
algorithm
Peter F. Lawrence, Ankur Chandra, Michael Wu, David Rigberg, Brian
DeRubertis, Hugh Gelabert, Juan Carlos Jimenez, Vicki Carter
Objectives: Endovenous closure is a common method to treat saphenous vein
incompetence. Despite attempts to prevent it, some patients have extension
of thrombus above the ideal site of closure immediately below the epigastric
vein. We have developed a classification system for the level of saphenous
vein closure to guide further therapy after endovenous treatment.
Methods: A six-tier classification system was developed, based on thrombus
proximity to the epigastric or femoral vein, and an algorithm for treatment,
based on level of closure was applied to all patients.
Results: Five hundred consecutive patients underwent radio-frequency abla-
tion of the saphenous vein; it was successfully closed in 498 (99.6%) patients.
Thirteen patients (2.6%) experienced thrombus bulging into the femoral vein or
adherent to its wall, which was treated with anticoagulation. All of these
patients had thrombus retraction to the level of the saphenofemoral junction
(SFJ) in an average of 16 days with concurrent anticoagulation. No femoral
deep venous thrombosis (DVT) occurred in the series. There was a significantly
higher rate of proximal thrombus extension in those patients with a history of
DVT and those with a great saphenous vein (GSV) diameter of>8 mm (P< .02).
Conclusions: A classification system for saphenous endovenous closure
which extends above the epigastric vein has been helpful in guiding manage-
ment. A GSV diameter at the SFJ of >8 mm and a history of DVT results in
significantly higher rates of proximal thrombus extension into the femoral
vein. A short course of LMWH, until clot retracts back into the saphenous
vein, is therapeutic. Management of the patients with thrombus flush with
the femoral vein wall still needs to be defined, but the outcome from these
patients is generally benign.
From the American Venous Forum
Prospective randomized study comparing the clinical outcomes between
inferior vena cava Greenfield and TrapEase filters
Fred Usoh, Anil Hingorani, Enrico Ascher, Alexander Shiferson, Nirav Patel,
Kapil Gopal, Natalia Marks, Theresa Jacob
Objective: Although anticoagulation remains the mainstay of treatment for
deep venous thrombosis, the use of inferior vena cava (IVC) filters when an-
ticoagulation has failed or when contraindicated remains a safe and
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filters are arguably among the most popular filtration devices. The Green-
field filter (12F introducer) has been in use for >30 years and has been well
studied. The TrapEase filter (6F introducer) has been used since 2000, with
a limited number of studies. Good guidelines to help determine which filter
to use in any given situation are lacking; therefore, this randomized study
prospectively compared the clinical outcomes (access-site thrombosis, filter
thrombosis, and symptomatic pulmonary embolism [PE]) between these
filters.
Methods: Between July 2006 and November 2008, 156 patients (63 men, 93
women; mean age, 75 years; range, 38-101 years) were randomized: 84 to
Greenfield and 72 to TrapEase IVC filter insertion in the infrarenal position
using angiographic guidance. Postoperative follow-up comprised serial lower
extremity and IVC/iliac vein (IV) duplex imaging (78.2%) at day 1, week 1,
every 3 months for the first year, and every 6 months for the second year;
clinical evaluation, and clinic visits. During this period, 349 patients (143
men, 206 women; mean age, 75 years; range, 24-96 years) were not
randomized.Result: The indications for filter placement, in the 156 randomized patients,
were gastrointestinal bleeding, 37; intracranial hemorrhage, 12; free-
floating clot, 19; failure of anticoagulation, 29; PE, 27; prophylactic, 4;
and others, 32. During a mean 12-month follow-up (range, 0-39 months),
symptomatic IVC/IV thrombosis developed in five patients (6.94%) in the Tra-
pEase group and none in the Greenfield group (P = .019). No filter migration,
access-site thrombosis, misplacement, or IVC perforation occurred. Recur-
rent PE was suspected in one of the five patients with IVC/IV thrombosis.
Overall mortality was 42.3% (66 patients), and 30-day mortality was 13.5%
(21 patients: 10 TrapEase, 11 Greenfield). The study was initially designed
to recruit 360 patients in both TrapEase and Greenfield filters in 2 years to
demonstrate any statistical significance but was prematurely concluded
due to the interim results.
Conclusion: A higher rate of symptomatic IVC/IV thrombosis is associated
with TrapEase filter placement. However, the TrapEase filter still has a selec-
tive clinical role in the prevention of thromboembolism in selected patients
who are coagulopathic. This is the first randomized prospective study
comparing IVC filters since their inception in 1967.
